VNRX - VolitionRx Limited

NYSE American - NYSE American Delayed Price. Currency in USD
3.0800
-0.0500 (-1.60%)
At close: 4:00PM EDT

3.0900 +0.01 (0.32%)
After hours: 6:56PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.1300
Open3.2000
Bid3.0600 x 1000
Ask3.1700 x 800
Day's Range3.0600 - 3.2000
52 Week Range2.2200 - 6.8400
Volume284,564
Avg. Volume252,845
Market Cap142.377M
Beta (5Y Monthly)1.90
PE Ratio (TTM)N/A
EPS (TTM)-0.4390
Earnings DateAug 11, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference
    PR Newswire

    Volition Announces Cameron Reynolds, President and Chief Executive Officer Invited as Presenter at Maxim's COVID-19 Virtual Conference

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that President and Chief Executive Officer, Cameron Reynolds has been invited to present at The Role of Cell Therapy and Clarity on Testing Conference organised by the Maxim Group.

  • VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock
    PR Newswire

    VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the closing of its previously announced underwritten public offering of an aggregate of 5,019,750 shares of common stock, including the exercise in full of the overallotment option, at a public offering price of $2.75 per share for total gross proceeds of $13.8 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Volition. All of the shares of common stock sold in the offering were offered by Volition.

  • VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock
    PR Newswire

    VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the pricing of its previously announced underwritten public offering. Volition is offering 4,365,000 shares of common stock, par value $0.001 per share, at a price to the public of $2.75 per share. In connection with the offering, Volition has also granted the underwriters a 30-day option to purchase up to an additional 654,750 shares of its common stock offered in the public offering, at the same public offering price per share, to cover overallotments, if any. All shares of common stock in the offering are being offered by Volition.

  • VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
    PR Newswire

    VolitionRx Announces Proposed Underwritten Public Offering of Common Stock

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any. All shares of common stock in the offering are being offered by Volition. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • VNRX: Q1 2020 Financial and Business Update
    Zacks Small Cap Research

    VNRX: Q1 2020 Financial and Business Update

    By Anita Dushyanth, PhD NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT Financial Update On May 7th, VolitionRx (NYSE:VNRX) reported financial results for their fiscal 2020 first quarter ending March 31st. Q1 OpEx was $5.8M, and significantly higher than Q4 2019. Net income and EPS were ($5.5) M and ($0.14). Although VNRX is conducting several studies related to COVID-19 and veterinary medicine,

  • PR Newswire

    VolitionRx To Present First Data on Nu.Q™ Capture Performance and Nu.Q™ Assay Performance in Lung Cancer and Blood Cancer at the 2020 ASCO Annual Meeting

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), an epigenetics company developing simple, easy to use and cost effective blood tests to help diagnose a range of cancers, will present three abstracts at the 2020 ASCO Annual Meeting.

  • VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update
    PR Newswire

    VolitionRx Limited Announces First Quarter 2020 Financial Results and Business Update

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2020. Volition management will host a conference call tomorrow, May 8 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.

  • VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update
    PR Newswire

    VolitionRx Limited Schedules First Quarter 2020 Earnings Conference Call and Business Update

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, May 8, at 8:30 a.m. Eastern time to discuss its financial and operating results for the first quarter 2020, in addition to providing a business update.

  • Is VolitionRx (NYSEMKT:VNRX) Using Too Much Debt?
    Simply Wall St.

    Is VolitionRx (NYSEMKT:VNRX) Using Too Much Debt?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers
    PR Newswire

    Volition's Nu.Q™ Vet Assay Detects Two Common Canine Cancers

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its first proof of concept study conducted by Texas A&M; University ("TAMU"). At a specificity of 90%, a single Nu.Q™ Vet assay detected almost 70% of both Canine Hemangiosarcoma and Canine Lymphoma with Areas Under the Curve ("AUC") of 84.5% and 83.1% cancer versus healthy, respectively. These two cancers alone represent almost a third of all canine cancers.

  • Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies
    PR Newswire

    Volition Files Patent for Nu.Q(TM) COVID-19 Triage Test and Commences Proof of Concept Studies

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.QTM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter.

  • VolitionRx Limited (NYSEMKT:VNRX) Is Expected To Breakeven
    Simply Wall St.

    VolitionRx Limited (NYSEMKT:VNRX) Is Expected To Breakeven

    VolitionRx Limited's (NYSEMKT:VNRX): VolitionRx Limited, a multi-national epigenetics company, engages in the...

  • VolitionRx Limited Releases Annual Corporate Brochure and Video
    PR Newswire

    VolitionRx Limited Releases Annual Corporate Brochure and Video

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today issued a Corporate Brochure and new Corporate Video detailing the company's mission, strategy, technology, recent achievements and future plans.

  • VolitionRx Limited to Present at Conferences in March 2020
    PR Newswire

    VolitionRx Limited to Present at Conferences in March 2020

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at five conferences in March 2020.

  • VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
    PR Newswire

    VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunction with the filing of its annual report on Form 10-K for the fourth quarter and full year ended December 31, 2019.

  • Volition Unveils Its Epigenetic Toolbox
    PR Newswire

    Volition Unveils Its Epigenetic Toolbox

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that research on its Nu.Q(TM) Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform. This epigenetic toolbox aims to initially be used in cancer diagnostics.

  • Does The VolitionRx Limited (NYSEMKT:VNRX) Share Price Tend To Follow The Market?
    Simply Wall St.

    Does The VolitionRx Limited (NYSEMKT:VNRX) Share Price Tend To Follow The Market?

    Anyone researching VolitionRx Limited (NYSEMKT:VNRX) might want to consider the historical volatility of the share...

  • VolitionRx Announces Filing of Registration Statements
    PR Newswire

    VolitionRx Announces Filing of Registration Statements

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has filed registration statements on Form S-3 and Form S-8, respectively, with the Securities and Exchange Commission.

  • Volition Develops a New Improved Nu.Q™ Assay Format
    PR Newswire

    Volition Develops a New Improved Nu.Q™ Assay Format

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided an update on its Nu Q™ Clinical Assays which use a magnetic particle-based assay format. Volition has completely re-engineered its Nu.Q™ assays leading to a step-change improvement in analytical performance. Volition expects this enhanced analytical performance to translate into improved clinical performance in the studies to be carried out and reported in the coming months.

  • VolitionRx Completes Acquisition of Octamer GmbH
    PR Newswire

    VolitionRx Completes Acquisition of Octamer GmbH

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the closing of the acquisition of the epigenetic reagent company Octamer GmbH ("Octamer") by its subsidiary Belgian Volition SPRL for approximately $725,000, consisting of cash and shares of restricted common stock of Volition. This strategic acquisition helps secure the supply of one of the key components of Volition's Nu.Q(TM) tests, the recombinant nucleosome used as the calibrant.

  • How Many VolitionRx Limited (NYSEMKT:VNRX) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many VolitionRx Limited (NYSEMKT:VNRX) Shares Did Insiders Buy, In The Last Year?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • VolitionRx Limited Announces Strategic Acquisition
    PR Newswire

    VolitionRx Limited Announces Strategic Acquisition

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced an agreement by its subsidiary Belgian Volition SPRL to acquire an epigenetic reagent company, Octamer GmbH ("Octamer"), for approximately $725,000 consisting of cash and shares of restricted common stock of Volition. The closing of the acquisition is subject to customary conditions and is expected to occur in January 2020. This strategic acquisition helps secure the supply of one of the key components of Volition's Nu.QTM tests, the recombinant nucleosome used as the calibrant.

  • VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test
    PR Newswire

    VolitionRx and Gyros Protein Technologies Awarded an Aggregate $1 million+ Eurostars Cash Grant to Collaborate on Developing a Lung Cancer Blood Test

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it was awarded $820,000 (€740,000 Euros) and Gyros Protein Technologies AB, now part of Mesa Laboratories Inc. (NASDAQ:MLAB) was awarded $230,000 (€206,000 Euros) each in the form of a non-repayable Eurostars cash grant. The grant proceeds are to be used towards the development of novel, high sensitivity assays and a validated panel ready for regulatory trials through the combination of Volition's propriety Nu.QTM platform and Gyros Protein Technologies' Gyrolab® technology. The resulting blood-based test will be used for triaging individuals testing positive in Low Dose CT lung cancer screening.

  • VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia
    PR Newswire

    VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

    VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced results from its latest proof of concept study. A single pre-clinical Nu.Q™ assay utilizing a basic microtiter plate platform detected 80% of newly diagnosed Non-Hodgkins Lymphoma ("NHL") and Leukemia cases (mixture of Acute Lymphocytic Leukemia ("ALL") and Acute Myeloid Leukemia ("AML") at 95% specificity among healthy subjects. The Area Under the Curve ("AUC") for this single assay was 91%. A number of other assays in development also demonstrated promising individual assay results with AUCs ranging from 79% to 91%.

  • PR Newswire

    VolitionRx Limited Announces Third Quarter 2019 Financial Results and Business Update

    AUSTIN, Texas, Nov 13, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2019. Volition management will host a conference call tomorrow, November 13, at 8:30 a.m. U.S. Eastern Time to discuss these results. Cameron Reynolds, President and Chief Executive Officer of Volition, upon releasing these results, commented, "I could not be more proud of our dedicated team at Volition, and the ground-breaking work we are doing.